Genocury
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genocury - overview
Established
2021
Location
Shenzhen, Guangdong, China
Primary Industry
Biotechnology
About
Based in Shenzhen, China, and established in 2021, Shenzhen Genocury Biotech Ltd. , trading as Genocury, is a biotechnology company that focuses on the R&D of f gene and cell therapies for cancers. The core R&D team has experience in the fields of cell therapy and gene therapy. In January 2026, Genocury raised a venture funding from VNTR Circle LLC..
The company mainly provides gene and cell therapies for tumours. Its products include vivo CAR-T (Chimeric Antigen Receptor T-Cell Therapy) for lymphoma, general NK cellular fluid for blood tumours, and CAR-NK (Chimeric Antigen Receptor NK Cell Therapy) for prostate, ovarian, pancreatic, and lung cancers, based on a gene editing technology platform, and an iPS hematopoietic directional differentiation platform. The in vivo CAR-T therapeutic drugs have completed preclinical development. The company generates revenue by providing gene and cell therapies for tumours.
Current Investors
Shenzhen HTI, Efung Capital, Vinno Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Oncology/Cancer Treatment
Website
www.genocury.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.